At a glance
- Originator Yung Shin Pharmaceutical
- Class Antihyperlipidaemics; Antiplatelets
- Mechanism of Action Platelet aggregation inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Thrombosis
Most Recent Events
- 10 Sep 1999 No-Development-Reported for Atherosclerosis in China (Unknown route)
- 10 Sep 1999 No-Development-Reported for Thrombosis in Taiwan (Unknown route)
- 28 Apr 1997 Preclinical development for Atherosclerosis in China (Unknown route)